287 completed, 51 unknown, 31 terminated, 14 recruiting. 111 Phase 4, 92 Phase 3, 77 Phase 2, 45 Phase 1, 23 Not applicable.
Follow Etanercept: new trials by email Literature Review of Etanercept trials Research Report on Etanercept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis Etanercept, Adalimumab, Upadacitinib - Arthritis, Rheumatoid | Not yet recruiting | Tufts Medical Center | 18 | 2026-09-01 | 2026-07-22 | |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis Injection, Etanercept, 25 Mg (Code May Be Used for Medicare When Drug Administered Under the Direct Supervision of A Physician, Not for Use When Drug is Self Administered) - Juvenile Idiopathic Arthritis | Phase 3 | Enrolling by invitation | University of Child Health Sciences and Children's Hospital, Lahore | 60 | 2026-01-27 | 2026-02-04 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD Ruxolitinib (JAKAVI®), Etanercept (Enbrel) - Graft vs Host Disease | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 122 | 2025-09-25 | 2026-07-07 |
| Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis Etanercept, Benzathine Penicillin, Placebo - Spondyloarthritis (SpA), Ankylosing Spondylitis (AS) | Phase 4 | Recruiting | Nanfang Hospital, Southern Medical University | 340 | 2025-06-14 | 2025-06-26 |
| Safety of a Strategy Combining Etanercept Administration With Repeated Contrast Ultrasound in Patients With Alzheimer's Disease etanercept and repeated contrast ultrasound - Alzheimer Disease | Phase 1 | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 5 | 2025-04-15 | 2026-05-12 |
| A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis MB04 (proposed biosimilar to etanercept), Enbrel (etanercept) - Rheumatoid Arthritis (RA) | Phase 3 | Completed | mAbxience Research S.L. | 501 | 2024-10-03 | 2026-10-08 |
| Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome Etanercept, Placebo - SAPHO Syndrome | Phase 2 / Phase 3 | Recruiting | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 60 | 2024-09-04 | 2026-04-13 |
| A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders MB04, US License Enbrel, EU Source Enbrel - Healthy Volunteers | Phase 1 | Completed | mAbxience Research S.L. | 141 | 2024-03-07 | 2025-09-30 |
| RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant Etanercept Injection [Enbrel] - Lung Transplant; Complications | Early Phase 1 | Enrolling by invitation | Northwestern University | 20 | 2023-09-17 | 2026-02-10 |
| Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success Ozanimod, TNF Inhibitor, Steroids - Ulcerative Colitis | Unknown | Insel Gruppe AG, University Hospital Bern | 240 | 2023-09-06 | 2023-12-06 | |
| NATIENS: Optimal Management and Mechanisms of SJS/TEN Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4 - Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses | Phase 3 | Completed | Vanderbilt University Medical Center | 2 | 2023-03-21 | 2025-12-17 |
| The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients Anti-TNF, JAK inhibitor - Rheumatoid Arthritis | Phase 3 | Withdrawn | Abu Dhabi Stem Cells Center | 2023-03-01 | 2025-10-06 | |
| Stand UP to Rheumatoid Arthritis (SUPRA) TNFi, Anti-IL6, JAKi - Rheumatoid Arthritis | Not applicable | Recruiting | Marie Hudson, MD | 75 | 2023-02-01 | 2026-02-03 |
| Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Etanercept, Vedolizumab - Type 1 Diabetes | Early Phase 1 | Completed | Benaroya Research Institute | 20 | 2022-09-21 | 2024-05-24 |
| TNF-α Treatment of Blast-Induced Tinnitus Etanercept, Saline - Tinnitus, Noise Induced | Phase 2 | Active not recruiting | Wayne State University | 88 | 2022-07-01 | 2026-10-20 |
| Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis. Infliximab: Adalimumab; Etanercept; - Rheumatoid Arthritis, Inflammatory Arthritis | Unknown | University of Sulaimani | 80 | 2022-03-01 | 2022-05-18 | |
| Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) - Rheumatoid Arthritis | Not applicable | Unknown | Medical University of Vienna | 85 | 2022-03-01 | 2021-11-15 |
| REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) Adalimumab and its biosimilars, Biological: Etanercept and its biosimilars, Golimumab - Ankylosing Spondylitis, Axial Spondyloarthritis | Phase 4 | Unknown | Hanyang University Seoul Hospital | 448 | 2022-01-15 | 2021-12-20 |
Showing 20 of 403. Sign in to see all of them.
Arthritis, Rheumatoid (136) · Psoriasis (67) · Spondylitis, Ankylosing (46) · Arthritis, Psoriatic (29) · Arthritis (22) · Arthritis, Juvenile (15) · Spondylarthritis (15) · Diabetes Mellitus, Type 1 (14) · Inflammation (13) · Axial Spondyloarthritis (7) · Graft vs Host Disease (7) · Spondylarthropathies (7) · Leukemia (5) · Skin Diseases (5) · Diabetes Mellitus (4)
Pfizer (52) · Amgen (48) · Wyeth is now a wholly owned subsidiary of Pfizer (40) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Massachusetts General Hospital (6) · Eli Lilly and Company (5) · University of Michigan Rogel Cancer Center (5) · Brigham and Women's Hospital (4) · Fred Hutchinson Cancer Center (4) · Innovaderm Research Inc. (4) · Sun Yat-sen University (4) · University of Leeds (4) · Biogen (3) · Charite University, Berlin, Germany (3) · Hanwha Chemical (3)
United States (139) · Germany (49) · France (40) · United Kingdom (39) · Poland (38) · Canada (36) · Hungary (35) · Spain (34) · Netherlands (31) · Czechia (27) · Italy (27) · Belgium (26) · China (23) · South Korea (23) · Australia (20)
Kyung-Sang Yu, M.D., Ph.D. (3) · Alexandra B Kimball, MD, MPH (2) · Andrew Posselt, MD, PhD (2) · Barbara K Finck, M.D. (2) · Bart L. Scott, MD (2) · Bernhard Hering, MD (2) · Gregory Yanik, MD (2) · James Shapiro, MD, PhD (2)
PMID 38488976, PMID 25913550, PMID 30473179, PMID 31277720, PMID 16636217, PMID 20124563, PMID 20957659, PMID 22155140, PMID 24907147, PMID 26072109, PMID 26953848, PMID 27175292, PMID 27299809, PMID 28074446, PMID 28255449, PMID 29843776, PMID 30465321, PMID 31122296, PMID 32845588, PMID 35279805, PMID 37140539, PMID 37341961, PMID 37400681, PMID 38521874, PMID 38647975, PMID 42011511, PMID 12115173, PMID 12905485, PMID 14627786, PMID 15229957, PMID 15248226, PMID 15517638, PMID 15751091, PMID 15838068, PMID 15843448, PMID 15948997, PMID 15986348, PMID 15996057, PMID 16342093, PMID 16378799, PMID 16399150, PMID 16463435, PMID 16481637, PMID 16622259, PMID 16646004, PMID 16782734, PMID 17092858, PMID 17113190, PMID 17199580, PMID 17373192
2016 (4), 2014 (3), 2005 (2), 2008 (2), 2009 (2), 2015 (2), 2018 (2), 2023 (2), U01HL069294 (2), 2017 (1), 2019 (1), F32DK068902 (1), P60AR047784 (1), R01AR049762 (1), R01DK109914 (1)